Letters to the Editor
19 June 2026
New papers
Aspirin underuse in secondary prevention: beyond access and adherence
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
4
Views
1
Downloads
Authors
To the Editor,
Cardiovascular disease remains the leading cause of mortality worldwide, yet aspirin, one of the most effective and inexpensive therapies for secondary prevention, continues to be underused across diverse healthcare settings and patient populations. Importantly, this underuse reflects not only limited access to therapy, but also disparities in adherence, persistence, and uncertainty regarding benefit in certain high-risk groups [...]
Altmetrics
Downloads
Download data is not yet available.
Citations
1. Yoo SGK, Chung GS, Bahendeka SK, et al. Aspirin for secondary prevention of cardiovascular disease in 51 low, middle, and high-income countries. JAMA 2023;330:71524.
2. Vora P, Soriano-Gabarró M, Russell B, Morgan Stewart H. Longterm adherence and persistence to low-dose aspirin for the prevention of cardiovascular disease: a population-based cohort study. Int J Clin Pract 2022;2022:7786174.
3. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. Circulation 2019;140:e596e646.
4. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021;42:322737.
5. Taliercio JJ, Nakhoul G, Mehdi A, et al. Aspirin for primary and secondary prevention of mortality, cardiovascular disease, and kidney failure in the Chronic Renal Insufficiency Cohort (CRIC) study. Kidney Med 2022;4:100547.
6. Shah SR, Alweis R, Ul Islam MY, et al. Effect of sociodemographic variables and other factors on the usage of different doses of aspirin in post-myocardial infarction patients: a cross-sectional study. Heart Views 2018;19:4953
How to Cite
1.
Mehmood F, Magsi N, Tariq A. Aspirin underuse in secondary prevention: beyond access and adherence. Global Cardiol [Internet]. 2026 Jun. 19 [cited 2026 Jun. 21];. Available from: https://www.globalcardiology.info/site/article/view/105
Copyright (c) 2026 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
